2-[(2,6-dipropyl-4-hydroxymethyl)phenoxy]-2-(3,4-ethylenedioxy-phenyl)acetic acid | 159590-42-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(2,6-dipropyl-4-hydroxymethyl)phenoxy]-2-(3,4-ethylenedioxy-phenyl)acetic acid
• 英文别名: 2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-[4-(hydroxymethyl)-2,6-dipropylphenoxy]acetic acid
• CAS: 159590-42-8
• 化学式: C₂₃H₂₈O₆
• 分子量: 400.472
• InChiKey: ZDGWHIXUTBGRNL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Peptides comprising non-natural amino acids and methods of making and using the same
  申请人：Longevity Biotech, Inc.

  公开号：US10543255B2

  公开（公告）日：2020-01-28

  This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.

  本发明涉及由天然多肽类似物组成的新型组合物，其中类似物包括一种α-氨基酸和至少一种β-氨基酸。给药组合物可用于治疗或预防由生化或生物途径功能障碍引起的多种疾病状态。本发明的组合物和方法特别适用于鉴定体内受体活性的新型治疗调节剂，与天然翻译的多肽相比，本发明的类似物具有更长的半衰期和相关的生物活性。
• Highly active polypeptides and methods of making and using the same
  申请人：Longevity Biotech, Inc.

  公开号：US10772934B2

  公开（公告）日：2020-09-15

  This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.

  本发明涉及由天然多肽类似物组成的新型组合物，其中类似物包括一种α-氨基酸和至少一种β-氨基酸。给药组合物可用于治疗或预防由生化或生物途径功能障碍引起的多种疾病状态。本发明的组合物和方法特别适用于鉴定体内受体活性的新型治疗调节剂，与天然翻译的多肽相比，本发明的类似物具有更长的半衰期和相关的生物活性。
• As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
  申请人：——

  公开号：US20020013304A1

  公开（公告）日：2002-01-31

  A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves administration of a pharmaceutical formulation containing an effective amount of an androgenic agent, wherein administration is on an as-needed basis rather than involving chronic pharmacotherapy. Local delivery may be accomplished via administration to the vagina, vulvar area or urethra of the individual, although oral administration is preferred for those androgenic agents that are orally active. Formulations and kits for carrying out the method are provided as well.

  提供了一种提高女性性欲和性反应能力的方法。该方法包括给药含有有效量雄性激素的药物制剂，其中给药是按需给药，而不是长期药物治疗。局部给药可通过给药到个人的阴道、外阴部或尿道来实现，但对于那些口服活性的雄性激素制剂来说，口服给药是首选。此外，还提供了用于实施该方法的制剂和试剂盒。
• Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
  申请人：——

  公开号：US20020099003A1

  公开（公告）日：2002-07-25

  Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal polypeptide (VIP) and VIP agonists is administered to the vagina and/or vulvar region of the individual undergoing treatment. The formulations are also useful for improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. Pharmaceutical formulations and kits are also provided.

  本研究提供了治疗女性性功能障碍的方法。将含有选自血管活性肠多肽（VIP）和 VIP 激动剂的血管活性剂的药物组合物施用到接受治疗者的阴道和/或外阴区域。这些制剂还可用于改善阴道肌肉张力和组织健康，提高阴道润滑度，减少过量胶原蛋白沉积。此外，还提供了药物制剂和试剂盒。
• As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
  申请人：——

  公开号：US20030022875A1

  公开（公告）日：2003-01-30

  A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves oral administration of a dosage form containing an effective amount of an orally active androgenic agent, and is on an as-needed basis rather than involving chronic pharmacotherapy. Oral pharmaceutical compositions, dosage forms and kits for carrying out the method are provided as well.

  提供了一种提高女性性欲和性反应能力的方法。该方法包括口服含有有效量口服活性雄性激素的剂型，并且是按需给药，而不是长期药物治疗。此外，还提供了用于实施该方法的口服药物组合物、剂型和试剂盒。